Answers are grounded in this paper and cite their sources.
Imipenem/relebactam demonstrated potent in vitro activity against NPE and P. aeruginosa isolates from IAIs and UTIs, including against resistant subsets, and will provide important coverage for IAIs and UTIs caused by β-lactam-resistant, MDR, and KPC-positive Gram-negative bacilli.
No takes yet. Share an insight, caveat, or question.
Karlowsky et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: